Patients with ESCC who did not have selected PD-L1 expression and were treated with PD-1 inhibitors demonstrated improved OS (HR = 0.73, 95% CI: 0.66-0.81) compared to those receiving standard chemotherapy. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.